Hope in cancer therapy: Radiopharmaceuticals making a comeback
Systemic radioactive medicines were first employed as therapies for cancer in the 1940s, when physicians utilized radioactive iodine for the treatment of thyroid cancer. However, the lack of potency and side effects relegated radiopharmaceuticals to the sidelines.
The advent of commercially available antibody-directed radiotherapeutics began at the turn of this century with the approval of Zevalin and Bexxar. But several key challenges—including the need for specialized facilities, equipment, and expertise—limited their commercial success.
Biopharma Dealmakers—a Nature publication—reports that the narrative has evolved dramatically with the advent of second-generation marvels such as Xofigo and Pluvicto. These advanced treatments, designed with enhanced safety and efficacy, have sparked a surge in investment and dealmaking within the field—with Novartis and Bayer leading the charge. On Wall Street, radiopharmaceutical companies are making waves—from IPOs to acquisitions.
Looking ahead, the future looks hopeful as second-generation radiopharmaceuticals venture into uncharted territories, extending their reach beyond treatment and even beyond oncology.
For more info on the present and future landscape of radiopharmaceuticals, view the full article on Biopharma Dealmakers.
To reach and collaborate with potential partners and investors for your cancer therapies, contact us about advertising with Biopharma Dealmakers.
About Biopharma Dealmakers
Providing timely information on dealmaking activity, Biopharma Dealmakers brings together life scientists, biotech and pharmaceutical professionals, and investors. Organizations seeking partners from the biopharma and investment community are invited to advertise and publish profile articles.
The publication is free to access at Nature.com/biopharmdeal and print issues are distributed to the readers of Nature Biotechnology and Nature Reviews Drug Discovery.
